TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07792681: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II/III Clinical Study Evaluating the Efficacy and Safety of BR005-036C Tablets in the Acute Treatment of Migraine in Adults

Sponsor: Brise Pharmaceuticals Co., Ltd. · Phase: PHASE2/PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 2079 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$3,976,224

Rescue Site Savings

+$2,603,480

Unlock Full NCT07792681 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07792681 Rescue Dossier →